Cue Biopharma shares to trade after IPO

Biotech company Cue Biopharma is set to begin trading in its public debut on Tuesday on Nasdaq under the ticker symbol "CUE." The company set its offering price at $7.50 per share on Dec. 27, selling 8.8 million shares to generate proceeds of $66 million. The underwriters are MDB Capital Group and Feltl and Company. The company is focused on developing complex biologic drugs targeting cancers and autoimmune disorders, and its core technology platform -- called CUE Biologics -- is in preclinical development, according to Cue Biopharma's prospectus. Cue Biopharma plans to move its lead drug candidate, CUE-101, which is intended for HPV-related cancers, into the clinic by the end of 2018.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.